BioSpace News Archive

Aerovate Therapeutics, Inc. (Aerovate), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced the appointment of veteran biotechnology leader Timothy Noyes as Chief Executive Officer.

Public Listing offers Access to CAD 52 Million from Share Subscription and Drawdown Agreement, Sufficient Funding to Complete Development and Launch Avisa BreathTest™ Pivotal Trials Planned in Post-COVID-19 Long Haulers and Ventilator-Associated Pneumonia

Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, today announced that the Institutional Review Board (“IRB”) at the University of the West Indies Hospital, in Jamaica has granted approval to commence the study of its sublingual psilocybin formulation (“CYB001”) in a Phase II clinical trial for patients suffering with Major Depressive Disorder (“MDD”).

ONI, a rapidly growing company redefining the boundaries of microscopy with its Nanoimager platform that enables imaging of individual molecules in living cells, today announced that Tyler Ralston, PhD, has joined the company as Chief Technology Officer (CTO).

Labcorp (NYSE: LH), a leading global life sciences company, today announced that members of the executive management team will participate in a virtual fireside chat at the UBS Global Healthcare Virtual Conference on Monday, May 24 at 3:00 p.m. ET.

AIM ImmunoTech Inc. (NYSE American: AIM) announces financial results for the first quarter ended March 31, 2021. As of March 31, 2021, AIM had cash, cash equivalents and marketable securities of $63.6 million, compared to $54.4 million as of December 31, 2020.

Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA ) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, today reported its financial results for the first quarter ended March 31, 2021 and provided a business update.

Abeona Therapeutics today announced financial results for the first quarter 2021 and recent business progress.

Harmony Biosciences Holdings, Inc. today announced that Harmony’s President and CEO, John C. Jacobs and Chief Medical Officer, Dr. Jeffrey Dayno will present a company update and host investor meetings at the Oppenheimer Rare and Orphan Disease Summit on Friday, May 21, 2021.

Newly Issued Claims Extend Patent Protection to Year 2039 for Nyxol ® Combination Therapy for Presbyopia Provides Broader Protection for Nyxol ® Across Indications on Methods of Use as Daily Administration